Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability of OraVescent fentanyl when used long-term to relieve breakthrough pain in opioid tolerant cancer patients.
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Cephalon
NCT07553000 · Wrist Injuries, Wrist Fracture, and more
NCT06382272 · Mastectomy, Breast, and more
NCT07231419 · Diabetic Peripheral Neuropathic Pain
NCT05468034 · Breast Cancer, Indolent Metastatic Breast Cancer
NCT06821607 · Chronic Low Back Pain
Cullman Oncology and Hematology
Cullman, Alabama
Advanced Clinical Research Institute
Anaheim, California
Pacific Cancer Medical Center
Anaheim, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions